SK Biopharmaceuticals: Major management decision
AI reading
★★★★★ Bullish · Material event
In-licensed new drug candidate for Parkinson's disease
Key figures: 계약규모 최대 4,307억·매출대비 61%
An AI model read the opening section of the filing and rated it relative to the company's size. It can be wrong, so check the original filing on DART (Korean).
Other filings by SK Biopharmaceuticals
- 09.23 ★★ Signed ₩63.3bn pharmaceutical supply agreement with US subsidiary
- 09.14 ★★★ Signed pharmaceutical supply agreement with subsidiary (internal transaction)
- 09.10 ★★★★ US FDA clinical hold notification for epilepsy drug candidate
- 08.26 ★★★★ In-licensed epilepsy drug candidate and platform technology
- 08.26 ★★★★ Asset acquisition for exclusive rights to new drug candidate and platform
For information only. Not investment advice.